C-Cath Injection Catheter gets CE mark

64

Cardio3 BioSciences has announced that it has received CE mark for its intra-myocardial C-Cath Injection Catheter. 

According to a company release, the C-Cath Injection Catheter is the most advanced device of its kind and was designed to address three key requirements: ease of use, safety and efficacy. During its development Cardio3 BioSciences combined its extensive experience in stem cell therapies and specific knowledge of the properties of heart tissue with key insights from leading cardiologists in the field. C-Cath’s performance is based on its unique needle design as well as unique catheter properties.

Pre-clinical data from a head to head comparison with the ‘best’ injection catheter available until now showed a close to threefold increase in retention of stem cells within the heart muscle in favour of the C-Cath Injection Catheter.

 

“Today marks an important milestone for Cardio3 BioSciences and our innovative C-Cath technology. With C-Cath, we developed an advanced injection catheter that meets the requirements of physicians and has the potential to deliver better outcomes for patients. C-Cath demonstrates our commitment to continued innovation in regenerative heart therapy. This is a major step forward in addressing the patient needs for regenerative therapies for the heart and provides physicians with new treatment options,” said Christian Homsy, CEO, Cardio3 BioSciences.